Obaid Ashraf, MD
Critical Care Medicine · Oklahoma City, OKNPI 1982056586
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (41.0%), food and beverage and education — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 65.0% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2023 at $4,675 and has fallen 76.8% since, to $1,085 in 2025. Among critical care medicine clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 125 payments — averaging $93.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$8K
- Insmed, Inc.$902
- Pinnacle Biologics, Inc$900
- AstraZeneca$453
- Inari Medical, Inc.$304
- GSK$267
- plus $1K from 14 others
What the payments were for
- Travel & lodging$4,81041%
- Food & beverage$3,85733%
- Education$3,07526%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 25 | $7,636 |
| Insmed, Inc. | 36 | $902 |
| Pinnacle Biologics, Inc | 1 | $900 |
| AstraZeneca | 8 | $453 |
| Inari Medical, Inc. | 3 | $304 |
| GSK | 16 | $267 |
| Boehringer Ingelheim | 5 | $236 |
| Pulmonx Corporation | 5 | $230 |
| Caris MPI, Inc. | 1 | $174 |
| Mylan Specialty L.p. | 10 | $150 |
| Haemonetics Corporation | 1 | $111 |
| Novartis | 4 | $110 |
| Abbott | 1 | $72 |
| Abiomed | 2 | $48 |
| Amgen | 2 | $40 |
| Mallinckrodt Hospital Products Inc. | 1 | $33 |
| Viatris Specialty LLC | 1 | $26 |
| Pfizer | 1 | $18 |
| Merck | 1 | $17 |
| Inspire Medical Systems, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,742 in reported general payments places this provider in the 95th percentile of 57 critical care medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 13 | $170,549 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 96 | $66,468 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 27 | $16,420 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $14,719 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $11,984 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $6,085 |
| Incruse ElliptaUmeclidinium Bromide | 15 | $5,215 |
| Wixela InhubFluticasone Propion/Salmeterol | 14 | $699 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $601 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 39 | $591 |
| Azelastine Hcl | 23 | $557 |
| Moxifloxacin Hcl | 17 | $460 |
| Montelukast Sodium | 25 | $406 |
| Prednisone | 110 | $336 |
| Omeprazole | 13 | $182 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat | $236 | $186,96940 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $267 | $86,402143 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $453 | $18,06839 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 57 critical care medicine providers in Oklahoma.
Other critical care medicine in Oklahoma City
- Michael HarperOklahoma City$6K
- Syed AnwerOklahoma City$4K
- Victoria KyleOklahoma City$4K
- Himanshu BhardwajOklahoma City$3K
- Mark RolfeOklahoma City$3K
- Brent BrownOklahoma City$2K
- Joseph BrewerOklahoma City$2K
- Mircea MihuOklahoma City$2K
- Laura SwantOklahoma City$1K
- Ali AshrafOklahoma City$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.